Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
1. BridgeBio's acoramidis approved in Japan for ATTR-CM. 2. AZN Alexion will handle Beyonttra's commercialization in Japan. 3. Positive trial outcomes include 0% mortality and significant event reduction. 4. BridgeBio to receive $30 million milestone upon approval. 5. Commercialization plans for acoramidis are set for early 2025.